Article
A Non-structural 1 Protein G53D Substitution Attenuates a Clinically Tested Live Dengue Vaccine.
Cell reports - 12 May 2020
Choy Milly M, Ng Dorothy H L, Siriphanitchakorn Tanamas, Ng Wy Ching, Sundstrom Karin B, Tan Hwee Cheng, Zhang Summer L, Chan Kitti W K, Manuel Menchie, Kini R Manjunatha, Chan Kuan Rong, Vasudevan Subhash G, Ooi Eng Eong
Abstract excerpt
The molecular basis of dengue virus (DENV) attenuation remains ambiguous and hampers a targeted approach to derive safe but nonetheless immunogenic live vaccine candidates. Here, we take advantage of DENV serotype 2 PDK53 vaccine strain, which recently and successfully completed a phase-3 clinical trial, to identify how this virus is attenuated compared to its wild-type parent, DENV2 16681. Site-directed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.